IP Library › Granted Patent US 7,645,898
Granted Patent B2
US 7,645,898 · App. 11/505,499 · Granted Jan 12, 2010

Selective androgen receptor modulators and method of use thereof

Assignee: University of Tennessee Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,645,898
App. No.
11/505,499
Granted
Jan 12, 2010
Kind
B2
Abstract

This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

Claims (8)

1. A SARM compound represented by the structure of formula (III):

and/or its isomer, pharmaceutically acceptable salt, or any combination thereof.

2. A composition comprising the SARM compound of claim 1 , and/or its isomer, or any combination thereof; and a suitable carrier or diluent.

3. A composition comprising the SARM compound of claim 1 , and/or its isomer, or any combination thereof, and/or a pharmaceutically acceptable salt thereof; and a suitable carrier or diluent.

4. A method of binding a SARM compound to an androgen receptor, comprising the step of contacting the androgen receptor with the SARM compound of claim 1 and/or its isomer, pharmaceutically acceptable salt, or any combination thereof, in an amount effective to bind the SARM compound to the androgen receptor.

5. A method of hormone therapy comprising the step of contacting an androgen receptor of a subject with the SARM compound of claim 1 and/or its isomer, pharmaceutically acceptable salt, or any combination thereof, in an amount effective to effect a change in an androgen-dependent condition.

6. A method of treating a subject suffering from prostate cancer, comprising the step of administering to said subject the SARM compound of claim 1 and/or its isomer, pharmaceutically acceptable salt, or any combination thereof, in an amount effective to treat prostate cancer in said subject.

7. A method of delaying the progression of prostate cancer in a subject suffering from prostate cancer, comprising the step of administering to said subject the SARM compound of claim 1 and/or its isomer, pharmaceutically acceptable salt, or any combination thereof, in an amount effective to delay the progression of prostate cancer in said subject.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2012
From: DALTON, JAMES T.; MILLER, DUANE D.; KIM, JUHYUN
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 028814/0604 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTIVE ASSIGNMENT TO RE-RECORD ASSIGNMENT PREVIOUSLY RECORDED UNDER REEL AND FRAME 018508/0764 PREVIOUSLY RECORDED ON REEL 018508 FRAME 0764. ASSIGNOR(S) HEREBY CONFIRMS THE INVENTOR 1 -DALTON, JAMES T. INVENTOR 2 - MILLER, DUANE D., ASSIGNING TO UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION. Recorded Nov 16, 2006
From: DALTON, JAMES T.; MILLER, DUANE D
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 018525/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2006
From: DALTON, JAMES T
To: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Reel/Frame 018508/0764 →
Continuity (5)
Continuation In Part 1135322500 · Feb 14, 2006
Continuation In Part 1112515900 · May 10, 2005
Continuation In Part 1106275200 · Feb 23, 2005
Continuation In Part 1086352400 · Jun 9, 2004
Related Publication 20070123563A1 · May 31, 2007